Literature DB >> 7074504

Cyclosporin A: a powerful immunosuppressant.

A Laupacis, P A Keown, R A Ulan, N McKenzie, C R Stiller.   

Abstract

Cyclosporin A (CyA) is a powerful immunosuppressive agent whose lack of myelotoxicity makes it unique among nonsteroidal drugs currently given for immunosuppression. It has been used with initial success in recipients of kidney, liver, bone marrow and pancreas transplants, and it may also have clinical application in the treatment of autoimmune disorders. In regard to its use in transplant recipients, there are many remaining questions about its mechanism of action, the optimum dose, whether it should be used alone or with other immunosuppressants, whether it can suppress chronic rejection and what its long-term side effects may be. These questions can only be answered by further careful laboratory investigation and controlled clinical trials. Until then, CyA should only be administered in centres experienced in its use.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074504      PMCID: PMC1863293     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  27 in total

1.  Cyclosporin A for psoriasis.

Authors:  W Mueller; B Herrmann
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

2.  Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.

Authors:  P J Tutschka; W E Beschorner; A C Allison; W H Burns; G W Santos
Journal:  Nature       Date:  1979-07-12       Impact factor: 49.962

3.  Cyclosporin A, a powerful immunosuppressant in vivo and in vitro in the dog, fails to induce tolerance.

Authors:  H J Deeg; R Storb; L Gerhard-Miller; H M Shulman; P L Weiden; E D Thomas
Journal:  Transplantation       Date:  1980-03       Impact factor: 4.939

4.  Cyclosporin relieves arthralgia, causes angioedema.

Authors:  D A Isenberg; M L Snaith; A A Al-Khader; S L Cohen; C Fisher; W J Morrow; J Mowbray
Journal:  N Engl J Med       Date:  1980-09-25       Impact factor: 91.245

5.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

6.  Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis.

Authors:  G Routhier; O Epstein; G Janossy; H C Thomas; P C Kung; G Goldstein
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

7.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

8.  The use of cyclosporin A and prednisone in cadaver kidney transplantation.

Authors:  T E Starzl; R Weil; S Iwatsuki; G Klintmalm; G P Schröter; L J Koep; Y Iwaki; P I Terasaki; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1980-07

9.  Studies on the immunosuppressive properties of cyclosporin a in rats receiving renal allografts.

Authors:  W P Homan; J W Fabre; K A Williams; P R Millard; P J Morris
Journal:  Transplantation       Date:  1980-05       Impact factor: 4.939

10.  Studies on the effects of cyclosporin A upon renal allograft rejection in the dog.

Authors:  W P Homan; M E French; P Millard; T G Denton; J W Fabre; P J Morris
Journal:  Surgery       Date:  1980-07       Impact factor: 3.982

View more
  24 in total

1.  Cardiopulmonary allotransplantation, a collective review: experimental progress and current clinical status.

Authors:  G A Painvin; I J Reece; D A Cooley; O H Frazier
Journal:  Tex Heart Inst J       Date:  1983-12

Review 2.  Molecular mediators of mesenchymal stem cell biology.

Authors:  Maria P Alfaro; Sarika Saraswati; Pampee P Young
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

Review 3.  Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds.

Authors:  Christopher T Walsh; Robert V O'Brien; Chaitan Khosla
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-31       Impact factor: 15.336

Review 4.  A fascinating journey into history: exploration of the world of isonitriles en route to complex amides.

Authors:  Rebecca M Wilson; Jennifer L Stockdill; Xiangyang Wu; Xuechen Li; Paul A Vadola; Peter K Park; Ping Wang; Samuel J Danishefsky
Journal:  Angew Chem Int Ed Engl       Date:  2012-02-24       Impact factor: 15.336

Review 5.  Structural mechanisms of cyclophilin D-dependent control of the mitochondrial permeability transition pore.

Authors:  Manuel Gutiérrez-Aguilar; Christopher P Baines
Journal:  Biochim Biophys Acta       Date:  2014-11-13

6.  Estrogen receptor beta modulates permeability transition in brain mitochondria.

Authors:  Suzanne R Burstein; Hyun Jeong Kim; Jasmine A Fels; Liping Qian; Sheng Zhang; Ping Zhou; Anatoly A Starkov; Costantino Iadecola; Giovanni Manfredi
Journal:  Biochim Biophys Acta Bioenerg       Date:  2018-03-14       Impact factor: 3.991

7.  Euryjanicins E-G, poly-phenylalanine and poly-proline cyclic heptapeptides from the Caribbean sponge Prosuberites laughlini.

Authors:  Edward Avilés; Abimael D Rodríguez
Journal:  Tetrahedron       Date:  2013-11-05       Impact factor: 2.457

8.  Local inflammation exacerbates cyclosporine a-induced gingival overgrowth in rats.

Authors:  Jianbin Guo; Wenyu Wang; Liyan Yao; Fuhua Yan
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

9.  Synthesis and screening of a cyclic peptide library: discovery of small-molecule ligands against human prolactin receptor.

Authors:  Tao Liu; Sang Hoon Joo; Jeffrey L Voorhees; Charles L Brooks; Dehua Pei
Journal:  Bioorg Med Chem       Date:  2008-01-13       Impact factor: 3.641

10.  Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites.

Authors:  D J Freeman; A Laupacis; P A Keown; C R Stiller; S G Carruthers
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.